GMJ Briefs
NEJM Volume 394 Reports Romiplostim’s Superior Efficacy Against Treatment-Related Platelet Depletion
NEJM Volume 394 trial confirms romiplostim significantly exceeds placebo effectiveness in preventing chemotherapy-induced thrombocytopenia in cancer patients.
What Thailand’s Parenting Trial Teaches Us About Violence Prevention Programmes
Key lessons from Thailand parenting trial: longer follow-up needed, awareness gains require conversion to sustained behaviour change, and risk-targeted approaches…
What Healthcare Leaders Should Know: The Economic Evidence Crisis in WHO Cancer Medicine Recommendations
Only 11% of WHO cancer medicine recommendations include cost data, yet African countries adopt them without adequate economic evidence for…
Immune Decline in Aging Disrupts Gut Microbiome Balance, Opening New Treatment Pathways
Aging-related immune decline allows harmful gut bacteria to proliferate, driving chronic inflammation and disease risk through microbiome imbalance.
Three Critical Lessons from Nigeria’s Healthcare Transformation Success
Three actionable insights from Nigeria's healthcare transformation: honest baseline assessment, primary care prioritization, and sustained multi-year leadership drive real change.
Stark Findings: Jewish NHS Staff Face Unique Workplace Ostracism
Jewish NHS staff emerge as only religious group experiencing systematic workplace ostracism, according to government antisemitism review.
What Clinicians Should Know About New Crohn’s Post-Operative Ultrasound Guidelines
New guidelines provide standardized ultrasound protocols to improve early detection and reduce invasive monitoring in post-surgical Crohn's patients.
New Data Highlights Global Burden of Hepatitis Delta as First Treatment Emerges
With 15-20 million people worldwide affected by hepatitis delta co-infection, FDA approval of Hepcludex offers the first treatment for this…